Lexaria Bioscience (LEXX) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Lexaria Bioscience's Strategic Initiatives and Phase 1b Study Propel Buy Rating
TipRanksDec 20, 2024 13:42 ET · Ratings
Lexaria Bioscience's Phase 1b Study Starts Patient Dosing, Says H.C. Wainwright
TipRanksDec 20, 2024 11:20 ET
Lexaria's Registered GLP-1 Study #4 Begins Dosing
AccesswireDec 19, 2024 09:05 ET
Express News | Lexaria Bioscience Corp - Unit Finalizes Project Agreement With Novotech
ReutersDec 18, 2024 13:11 ET
Lexaria Bioscience Bolsters Drug Delivery Strategy
TipRanksDec 18, 2024 12:42 ET
Lexaria Forms New Scientific Advisory Board
AccesswireDec 18, 2024 09:25 ET

Comments

71843878

Dec 26, 2024 07:59

$Lexaria Bioscience (LEXX.US)$ $2.8/3 could b before year ends?

1

Jaguar8

Dec 19, 2024 08:08

NEWS

$Lexaria Bioscience (LEXX.US)$
Lexaria's Registered GLP-1 Study #4 Begins Dosing
Thursday, 19th December at 9:05 am
Registered Phase-1b 12-week study will investigate safety, diabetes control, and weight loss
KELOWNA, BC / ACCESSWIRE / December 19, 2024 / Lexaria Bioscience Corp. (NASDAQ: LEXX)(NASDAQ: LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has begun dosing in the Company's Phase 1b, 12-week chronic study GLP-1-H24-4, (the "Study"). Th...

1

71843878

Dec 19, 2024 07:15

next $Lexaria Bioscience (LEXX.US)$

@104088143：like

Nukkleus shares extend rally, jumping nearly 36% in premarket trading, after soaring approximately 327% in the previous session.

1

71843878

Dec 12, 2024 11:41

$Lexaria Bioscience (LEXX.US)$ looks like someone w deep pockets is shorting our play....sad.

Jaguar8

Nov 26, 2024 08:21

NEWS

$Lexaria Bioscience (LEXX.US)$
Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs
Lexaria Bioscience provides a strategic update on the expanding therapeutic benefits of GLP-1 drugs, highlighting their growing applications beyond diabetes and weight loss. The market, dominated by semaglutide and tirzepatide, has seen remarkable growth from $300 million in 2018 to projected $30 billion in 2024. New therapeutic applications being investigated include he...

1

LEXX Lexaria Bioscience

Trade Overview

Capital Trend

News

Comments